Brazil's health regulator Anvisa is looking into 13 reports of an illness that leads to vision loss in people who used weight-loss pens, according to G1. The notifications connect the condition to this class of injectable obesity drugs.
G1 did not say in the headline or summary which specific products or active ingredients are named in the reports, where in Brazil the cases occurred, or when the notifications were filed. The outlet also did not indicate the ages or health status of the people involved, or whether any cases have been confirmed as linked to the medication.
Anvisa has not publicly announced a conclusion, and no recall or suspension of any product has been reported in the material available.
The regulator routinely opens investigations when it receives reports of suspected adverse reactions to medicines sold in Brazil. Such reviews typically involve checking whether a reported event meets the criteria for a confirmed link to the drug, a step that can take time and may end without any finding against the product.
Weight-loss pens have drawn growing attention in Brazil and elsewhere as demand for the treatments has risen. Regulatory scrutiny of side effects has followed that increase in use.
What to watch next: whether Anvisa publishes its findings on the 13 notifications and whether the review leads to any change in how these products are labeled or prescribed in Brazil.
